N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

Sponsor: Merck Sharp & Dohme LLC • ClinicalTrials.gov ID: NCT06655324

Registry updated: 2026-09-17
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.

Interventions

  • V350A (Biological)
    Vaccination administered via intramuscular injection
  • V350B (Biological)
    Vaccination administered via intramuscular injection
  • Placebo (Biological)
    Vaccination administered via intramuscular injection

Eligibility criteria

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization. * Has a body mass index between 18 and 38 kg/m\^2, inclusive, for adults 18-30; has a body mass index between 15 and 38 kg/m\^2, inclusive, for adolescents 12-17. Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment. * Has any immunosuppressive medical condition or receive any immunosuppressive therapy.

Conditions

Healthy

Locations

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0011) — Glendale, California, United States
  • QPS-MRA, LLC ( Site 0012) — South Miami, Florida, United States
  • Alliance for Multispecialty Research, LLC ( Site 0008) — Kansas City, Missouri, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016) — Springfield, Missouri, United States
  • Velocity Clinical Research Lincoln ( Site 0004) — Lincoln, Nebraska, United States
  • Velocity Clinical Research, Omaha ( Site 0005) — Omaha, Nebraska, United States
  • Remington-Davis, Inc. ( Site 0017) — Columbus, Ohio, United States
  • Lynn Health Science Institute ( Site 0010) — Oklahoma City, Oklahoma, United States
  • Alliance for Multispecialty Research, LLC ( Site 0009) — Knoxville, Tennessee, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record